Revolution Medicines, Inc. (RVMD)
Market Cap | 7.56B |
Revenue (ttm) | 742,000 |
Net Income (ttm) | -567.06M |
Shares Out | 168.22M |
EPS (ttm) | -3.56 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,243,695 |
Open | 46.03 |
Previous Close | 46.43 |
Day's Range | 44.91 - 46.82 |
52-Week Range | 25.58 - 62.40 |
Beta | 1.40 |
Analysts | Strong Buy |
Price Target | 62.77 (+39.71%) |
Earnings Date | Nov 6, 2024 |
About RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clin... [Read more]
Financial Performance
In 2023, Revolution Medicines's revenue was $11.58 million, a decrease of -67.27% compared to the previous year's $35.38 million. Losses were -$436.37 million, 75.5% more than in 2022.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for RVMD stock is "Strong Buy." The 12-month stock price forecast is $62.77, which is an increase of 39.71% from the latest price.
News
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
Underwriters' full exercise of option brings gross proceeds to $862.5 million Underwriters' full exercise of option brings gross proceeds to $862.5 million
Revolution Medicines: Risky Buy On Recent Share Price Dip
Revolution Medicines' stock has surged over 30% since April, driven by promising clinical data for its lead asset, RMC-6236, targeting RAS-mutated cancers. RMC-6236 shows best-in-class efficacy in PDA...
Top 3 Health Care Stocks That Could Blast Off In December
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants
REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer...
Revolution Medicines Announces Commencement of Public Offering of Common Stock
REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer...
Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio
Compelling Phase 1/1b update on RMC-6236 monotherapy in second-line metastatic pancreatic ductal adenocarcinoma supports ongoing Phase 3 RASolute 302 clinical trial
Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer...
Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Call Transcript
Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Call Transcript
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress
Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), supported by compelling clinical profile
Revolution Medicines to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today annou...
Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer...
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
First clinical results for RMC-9805, a RAS(ON) G12D-selective inhibitor, demonstrate encouraging tolerability and antitumor activity in patients with PDAC
Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Encouraging progression-free survival and overall survival profile Safety findings consistent with previously reported data, no new safety signals observed Investor webcast to be held Friday, October ...
Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma
REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer...
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective inhibitor) monotherapy studies to be featured in two late-breaking ...
Revolution Medicines, Inc. (RVMD) Q2 2024 Earnings Call Transcript
Revolution Medicines, Inc. (NASDAQ:RVMD) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Ryan Asay - Senior Vice President of Corporate Affairs Mark Goldsmith - Chairm...
Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress
REDWOOD CITY, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer...
Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024
REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer...
Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter
As of July 16, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in prec...
Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024
REDWOOD CITY, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer...
Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer...
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers...
Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers...
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
Simultaneous publication and presentation of RMC-6236 chemical structure, preclinical data and case studies during the “KRAS: Broadening the Attack Beyond G12C with Small Molecules and Immuno-Oncology...